News 2023-07-28
[Important Notice] Porton Announcement Regarding the Change of Email Domain
Dear valued customers and partners,
We would like to extend our gratitude for your continuous support towards Porton Pharma Solutions Ltd. In order to further enhance the company's brand recognition, adapt to our global development strategy, improve communication efficiency, and protect each other's information security, we have decided to change our email domain name from porton.cn to portonpharma.com.
We will be discontinuing the use of the old email addresses and will automatically forward all emails sent to the old addresses to the new address in the coming weeks or so. To avoid any unnecessary delays, we strongly recommend that you start using the new email address to contact us starting from August 13, 2023.
We look forward to maintaining closer contact with you and achieving greater business success together. If you have any questions or need further assistance, please feel free to contact us at any time.
We apologize for any inconvenience caused by this change and appreciate your understanding!
Website: www. portonpharma.com
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).

News 2025-04-11
Porton Newsletter - Q1 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities